What is IGF-1 LR3?
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant variant of human Insulin-like Growth Factor-1 (IGF-1). Unlike native IGF-1, this molecule incorporates two key structural modifications: a substitution of glutamate for arginine at position 3, and an N-terminal extension of 13 additional amino acids.
These modifications are not cosmetic: they dramatically reduce the molecule’s affinity for IGFBPs (Insulin-like Growth Factor Binding Proteins), which under normal conditions capture and neutralize native IGF-1 in circulation. By escaping this regulatory system, IGF-1 LR3 remains biologically active for a significantly longer period.
Important: IGF-1 LR3 is not FDA-approved for human use. The information on this page summarizes findings from scientific literature and is provided for educational purposes only. It does not constitute medical advice or a recommendation for use.
Mechanism of Action
IGF-1 LR3 exerts its effects primarily through activation of IGF-1R receptors (receptor tyrosine kinase), which are expressed in skeletal muscle, adipose tissue, liver, and other tissues.
Primary molecular pathways:
- PI3K/Akt/mTOR: Stimulates muscle protein synthesis and suppresses proteolysis (direct anti-catabolic effect).
- MAPK/ERK: Promotes cell proliferation, including activation and proliferation of satellite cells (skeletal muscle stem cells).
- Lipolysis: At the level of adipose tissue, activates hormone-sensitive lipase and promotes fatty acid oxidation.
The critical difference from native IGF-1 lies in pharmacokinetics: IGF-1 LR3 has a half-life of 20-30 hours, compared to approximately 15 minutes for endogenous IGF-1. This extension occurs because the Arg3 modification reduces binding to IGFBP-3, the main transporter that limits the bioavailability of native IGF-1.
Hyperplasia vs. hypertrophy: One aspect that distinguishes IGF-1 LR3 in research literature is its reported capacity to stimulate not only the thickening of existing muscle fibers (hypertrophy), but also an increase in the number of fibers through satellite cell proliferation (hyperplasia). This mechanism differs from that of classical androgenic anabolic compounds.
Reported Research Protocol
The following table summarizes ranges described in research literature and animal model reports. This does not constitute a recommended dosage for humans.
| Parameter | Reported Range |
|---|---|
| Starting dose | 20-40 mcg/day SC |
| Maintenance dose | 40-80 mcg/day SC |
| Maximum reported dose | 100 mcg/day SC |
| Route of administration | Subcutaneous |
| Frequency | Once daily |
| Typical cycle in animal models | 4-8 weeks |
Vial reconstitution (1 mg):
- Add 1.0 mL of bacteriostatic water (BAC water) or 0.1% acetic acid (preferred for greater protein stability).
- Resulting concentration: 1 mg/mL (1,000 mcg/mL).
- Example: for 50 mcg → 0.05 mL (5 units on a U-100 insulin syringe).
Effects Reported in Literature
Preclinical studies have described the following effects in animal models:
- Muscle protein synthesis: Direct activation of mTOR independent of GH (growth hormone), making it active even in the absence of pituitary signaling.
- Satellite cell proliferation: Potential increase in the total number of muscle fibers.
- Lipolysis: Activation of fatty acid oxidation in adipose tissue.
- Anti-catabolic effect: Suppression of protein degradation pathways (ubiquitin-proteasome).
- Tissue repair: In vitro studies report acceleration of repair processes.
Described Adverse Effects
Adverse effects identified in research include:
- Hypoglycemia: IGF-1 LR3 has insulin-like activity at insulin receptors. It can cause blood glucose drops, especially if administered without close carbohydrate intake.
- Water retention: Similar to that observed with native IGF-1 and GH; especially in early phases.
- Post-injection hypoglycemia: Particularly relevant in the context of prolonged fasting.
- Adipose tissue growth at high doses: Despite the lipolytic effect, very high sustained doses may promote adipogenesis in certain tissues.
- Theoretical oncological risk: IGF-1R is overexpressed in several cancer types; chronic stimulation of this pathway is an active area of study. Ongoing research is not conclusive.
Storage
IGF-1 LR3 is one of the most sensitive molecules in the research peptide catalog. Improper handling irreversibly degrades the protein.
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unreconstituted) | -80°C (ideal) / -20°C (acceptable) | Up to 12-24 months |
| Reconstituted | 2-8°C (refrigeration) | Maximum 14 days |
| Room temperature | Not recommended | Rapid degradation |
Critical warning: IGF-1 LR3 is extremely sensitive to freeze-thaw cycles. Each cycle irreversibly degrades the protein structure. Once reconstituted, do not refreeze.
Legal disclaimer: This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.
Reported protocol (research reference)
| Vial sizes | 1 mg |
|---|---|
| Reported dose | Research literature reports ranges of 20-100 mcg/day SC. This is not a therapeutic use recommendation. |
| Half-life | 20-30 hours, compared to ~15 minutes for native IGF-1, due to reduced affinity for IGFBP binding proteins. |
| FDA status | Not FDA approved |